On January 8, 2020 ArcherDX, Inc., a molecular diagnostics company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, reported that Jason Myers, Ph.D., Chief Executive Officer, will present an overview of the company and its products at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California (Press release, ArcherDX, JAN 8, 2020, View Source [SID1234552881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event:

38th Annual J.P. Morgan Healthcare Conference

Presenter:

Jason Myers, Ph.D., Chief Executive Officer, ArcherDX

Date:

Tuesday, January 14, 2020

Time:

9:00 a.m. Pacific Time

Dr. Myers will outline ArcherDX’s plans to introduce IVD test kits for pan-solid tumor companion diagnostics (STRATAFIDE) and personalized cancer monitoring, which, once approved, will enable individualized genomic cancer treatment to be practiced at any level of the health care system, from academic centers to community practices. He will also provide an update on the growing demand for on-site and local genomic testing for both research and clinical applications.